Table I.
Patient characteristics and corresponding level of plasma cfDNA.
| Characteristic | Number (%) N=62 | cfDNA, ng/ml (95%CI) | P-value |
|---|---|---|---|
| Sex | 0.3 | ||
| Male | 38(61) | 0.91 (0.75-0.99) | |
| Female | 24(39) | 0.97 (0.86-1.33) | |
| Age | 0.4 | ||
| Median | 61.3 | ||
| Range | 40.8-74.8 | ||
| ≤65 | 0.91 (0.76-0.99) | ||
| >65 | 0.98 (0.77-1.44) | ||
| Performance status | <0.001 | ||
| 0 | 54(87) | 0.90 (0.75-0.94) | |
| 1 | 6(10) | 1.97 (1.07-2.74) | |
| 2 | 2(3) | 3.02 (2.51-3.52) | |
| Site of primary | 0.4 | ||
| Colon | 42(68) | 1.08 (0.91-1.68) | |
| Ascending | 11(18) | ||
| Transverse | 1 (1.5) | ||
| Descending | 3 (4.5) | ||
| Sigmoid | 27(44) | ||
| Rectal | 20(32) | 0.96 (0.86-1.28) | |
| Debut of metastases | 0.6 | ||
| Synchronous | 33(53) | 1.16 (0.98-1.84) | |
| Metachronous | 29(47) | 1.50 (0.94-2.05) | |
| Response | 0.02 | ||
| CR+PR | 56(90) | 0.91 (0.76-0.98) | |
| SD+PD | 4(7) | 1.79 (0.99-2.57) | |
| Not RECIST | 2(3) | ||
| KRAS status | 0.21 | ||
| Wt | 36(58) | 0.87 (0.75-0.98) | |
| mut | 26(42) | 1.01 (0.89-1.29) |
cfDNA, cell free DNA; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; KRAS, Kirsten RAt Sarcoma oncogene; Wt, wild type; mut, mutation.